BioSpace News Archive

MiMedx Group, Inc. today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present during the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12 at 5:15 PM EST.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant.

AMO Pharma Limited today announced the completion of activation of two additional clinical trial sites in Australia and New Zealand for its pivotal REACH-CDM study evaluating the efficacy and safety of the investigational therapy AMO-02.

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly ® ) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy.

Acer Therapeutics Inc. (Nasdaq: ACER), today announced that Acer’s management team will participate in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference.

Agenus (NASDAQ: AGEN), today announced the publication of results in the Journal of Clinical Oncology (JCO) from a global Phase 2 clinical study of balstilimab (Bal) plus zalifrelimab (Zal) in second-line (2L) recurrent/metastatic cervical cancer patients who had relapsed after treatment with platinum-based therapy.

Sunshine Biopharma Inc. today announced that on December 20, 2021, the Company issued 2,904,833 shares of Common Stock in favor of RB Capital Partners, Inc.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has entered into definitive agreements with each of Idaho Molecular Inc. and Advanced Conceptions, Inc., pursuant to which each of them will become wholly owned subsidiaries of Co-Dx.

Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen’s NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer’s disease indications.

Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE ™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients.